Therapeutic Innovation & Regulatory Science, published by Springer Heidelberg, is an esteemed journal that focuses on the intersection of therapeutic innovations and the regulatory frameworks that govern them. Established in 1970 and continuing its legacy of excellence through converged years, this journal plays a crucial role in supplying cutting-edge research, reviews, and discussions that advance understanding in the fields of pharmacology and healthcare regulation. With an impact factor reflective of its rigorous peer-review standards, this journal holds a prestigious Q1 ranking in Pharmacology, Toxicology, and Pharmaceutics (Miscellaneous) for 2023, reflecting its influence and the high quality of its published material. The journal's wide scope also embraces public health and environmental studies, making it an essential resource for researchers and professionals navigating these critical areas. Open access options enhance its visibility and accessibility, ensuring that the latest discoveries and regulatory insights are readily available to a global audience. For those at the forefront of medicinal science and regulatory affairs, Therapeutic Innovation & Regulatory Science is your avenue to understanding pivotal innovations that shape contemporary therapeutic practices.

The Cochrane Database of Systematic Reviews is a premier journal published by WILEY, focusing on the critical appraisal and synthesis of high-quality research in health care. With its dedication to evidence-based practice, this journal serves as a cornerstone for researchers, healthcare professionals, and students alike, offering pivotal insights through rigorous systematic reviews. Although it is not an open-access publication, its influence in guiding clinical decision-making and policy formulation is profound, underscored by its contributions to the advancement of healthcare knowledge. Based in the United States at 111 River St, Hoboken, NJ, the Cochrane Database has established itself as essential reading for those seeking to stay at the forefront of systematic reviews and meta-analyses in the medical field, ensuring that users are well-equipped with the evidence necessary for informed practice.

Istanbul Medical Journal is a prominent open-access journal published by GALENOS PUBL HOUSE, dedicated to disseminating high-quality research in the field of medicine since its inception in 1994. The journal, identifiable by its ISSN 2619-9793 and E-ISSN 2148-094X, serves as a critical platform for healthcare professionals, researchers, and students who aim to share innovative studies and advancements within diverse medical domains. Its commitment to open access ensures that crucial findings and discussions are readily available to a global audience, fostering collaboration and knowledge exchange among the scientific community. Located in Istanbul, Türkiye, the journal not only contributes to the medical literature landscape but also emphasizes the importance of accessibility in research, aligning with current academic trends that prioritize the transmission of knowledge across barriers. As a resource for those involved in healthcare and medical research, the Istanbul Medical Journal plays a vital role in shaping future developments in medicine.

Global Journal of Medical Pharmaceutical and Biomedical Update, published by SCIENTIFIC SCHOLAR LLC, is a premier platform dedicated to advancing knowledge in the fields of medicine, pharmaceuticals, and biomedical sciences. With an E-ISSN of 2765-8910, this journal aims to foster innovative research and insightful discussions by providing open access to high-quality peer-reviewed articles. It serves as an invaluable resource for researchers, professionals, and students alike, ensuring that the latest advancements, methodologies, and findings are accessible to a diverse audience. Located at 50, Woodgreen Dr, Pittsford, NY 14534, the journal prioritizes the dissemination of critical information that addresses the evolving challenges faced in healthcare and biomedical research, ultimately contributing to the betterment of global health outcomes.

Complementary Therapies in Clinical Practice is a premier academic journal published by Elsevier Science Ltd, dedicated to advancing the field of complementary and alternative medicine. With an impressive impact factor placing it in the Q1 category for its field and a Scopus rank of 16 out of 105, it serves as a vital platform for sharing high-quality research and clinical insights. Established in 2005 and continuing through 2024, the journal is committed to disseminating evidence-based practices that enhance patient care and safety. Although it does not offer open access, the journal remains integral to researchers, clinicians, and students striving to integrate complementary therapies within conventional healthcare frameworks. Based in the United Kingdom, the journal not only promotes scholarly discourse but also fosters collaboration across an international community of practitioners dedicated to innovative therapeutic approaches.

The American Journal of the Medical Sciences, published by Elsevier Science Inc, has been a cornerstone in the field of medicine since its inception in 1945. With ISSN 0002-9629 and E-ISSN 1538-2990, this esteemed journal provides a comprehensive forum for the dissemination of cutting-edge research and clinical advancements across various medical disciplines. It currently holds a distinguished Q2 ranking in the field of Medicine (miscellaneous) and ranks #118 out of 636 in General Medicine on Scopus, reflecting its significant impact with an 81st percentile rating. While it operates under a traditional publishing model, which ensures rigorous peer-review processes, its commitment to disseminating vital medical knowledge remains paramount. Based in the United States at STE 800, 230 Park Ave, New York, NY 10169, the journal aims to bridge the gap between research and practice, making it an invaluable resource for researchers, healthcare professionals, and students dedicated to advancing medical science and improving patient care.

Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

Trials, published by BMC, is a leading open access journal that has been pioneering advancements in the field of medicine and pharmacology since its inception in 2006. With an impressive E-ISSN of 1745-6215, the journal is based in the United Kingdom and operates from its address at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND. Trials is recognized for its impactful contributions to the research community, achieving a Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories according to the 2023 category quartiles. This esteemed journal aims to provide a platform for presenting cutting-edge clinical trials and methodological advances, effectively fostering collaboration and innovation among researchers, professionals, and students. The journal's accessibility, supported by its open access model, enhances the visibility and dissemination of vital research findings, ensuring that every contribution reaches a broad audience. As of 2024, Trials continues to be a crucial resource for anyone passionate about exploring new frontiers in medical research.

Functional Foods in Health and Disease is a respected peer-reviewed journal published by FUNCTIONAL FOOD CENTER INC, dedicated to advancing research in the fields of biochemistry, food science, medicine, and nutrition. Since its inception in 2011, this journal has provided a platform for innovative studies that connect the impact of functional foods on health and disease outcomes. With a focus on interdisciplinary research, it aims to disseminate knowledge that enhances the understanding of how specific food components can influence health and well-being. The journal is indexed with an ISSN of 2160-3855 and annually ranked in several categories, including Q4 in Biochemistry and Q3 in Food Science, Medicine, and Nutrition and Dietetics for 2023. As an open access publication, it ensures that research is widely accessible, which is crucial for fostering collaboration and discussion within the scientific community. This journal is a vital resource for researchers, practitioners, and students seeking to explore the dynamic role of functional foods in health promotion and disease prevention.

PHARMACEUTICAL STATISTICS is a premier academic journal published by Wiley, focusing on the intersection of pharmacology and statistics. With the ISSN 1539-1604 and E-ISSN 1539-1612, this journal has established itself as a leading resource in the field since its inception in 2004, with a targeted convergence year extending to 2024. Notably, it ranks in the Q1 category for both pharmacology and statistics, reflecting its high impact and significance within these disciplines. The journal embraces a wide scope, encompassing statistical methodology and its application in pharmaceuticals, thus serving as an essential platform for researchers, professionals, and students committed to advancing their knowledge and practice. Its notable placement in Scopus rankings further reinforces its academic credibility, making it a valuable reference point for high-quality research. Although this journal does not currently offer open access options, it remains a vital source of insights and research advancements in the pharmaceutical sciences.